Outcomes in children with central nervous system tumors disseminated at presentation: a large single-center experience

被引:2
|
作者
Kirkman, Matthew A. [1 ,2 ]
Hayward, Richard [1 ]
Phipps, Kim [1 ]
Aquilina, Kristian [1 ]
机构
[1] Great Ormond St Hosp Sick Children, Dept Neurosurg, London WC1N 3JH, England
[2] Natl Hosp Neurol & Neurosurg, Victor Horsley Dept Neurosurg, Queen Sq, London, England
关键词
Central nervous system tumors; Event-free survival; Overall survival; Recurrence; LEPTOMENINGEAL DISSEMINATION; PILOCYTIC ASTROCYTOMA; MEDULLOBLASTOMA; CHEMOTHERAPY; DIAGNOSIS;
D O I
10.1007/s00381-018-3871-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose Children with disseminated central nervous system (CNS) tumors have worse outcomes than those with solitary disease, but outcomes of disease dissemination at initial presentation have not been systematically studied and compared across tumor groups to date. We evaluated the impact of tumor dissemination at presentation on management and clinical outcomes in a cohort of consecutively treated children in a single neurosurgical unit over a 14-year period. Methods Method used was a retrospective review of data on children presenting to Great Ormond Street Hospital, London, UK, with medulloblastoma, primitive neuroectodermal tumor, atypical teratoid rhabdoid tumor, pilocytic astrocytoma, and ependymoma between 2003 and 2016 inclusive. Uni- and multi-variate analyses were performed to evaluate a range of outcome measures. Results Three-hundred sixty-one children were identified in total, 53 with disease dissemination at presentation (M:F = 34:19, median age = 3.8 years, range = 7 days-15.6 years) and 308 with solitary tumors (M:F = 161:147, median age = 5.8 years, range = 1 day-16.9 years). Median follow-up was similar irrespective of dissemination status (disseminated tumor 64.0 months, range = 5.2-152.0 months; solitary tumor 74.5 months, range = 4.7-170.1 months; P > 0.05). In multivariate analyses, tumor type and dissemination status at presentation were significantly associated with overall survival (P < 0.0001), risk of recurrence/disease progression (P < 0.01), and event-free survival (P < 0.0001). Subtotal resection was associated with shorter time to recurrence/disease progression (P < 0.01) and worse event-free (P < 0.0001) but not overall survival, whereas treatment with chemotherapy and radiotherapy were associated with improved overall (Ps < 0.0001) and event-free survival (Ps < 0.05). Differences between tumor groups were evident. Conclusions Dissemination status at initial presentation significantly affects outcomes in children with CNS tumors.
引用
收藏
页码:2259 / 2267
页数:9
相关论文
共 50 条
  • [31] Nimotuzumab Therapy in Treatment of Paediatric Central Nervous System Tumors: Single Center Experience
    Akyuz, C.
    Varan, A.
    Bayhan, T.
    Aydin, B.
    Yalcin, B.
    Kurucu, N.
    Kalkan, N.
    Bajin, I.
    Babacan, A.
    Kutluk, T.
    PEDIATRIC BLOOD & CANCER, 2016, 63 : S129 - S129
  • [32] HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR CENTRAL NERVOUS SYSTEM TUMORS: A SINGLE CENTER EXPERIENCE
    Zecchin, Victor
    Cappellano, Andrea
    Saba, Nasjla
    Cavalheiro, Sergio
    Dastoli, Patricia
    Mendonca, Ana Cristina
    Guimaraes, Renata
    Fernandes Junior, Virginio
    Monteirio, Cintia
    Ibanez, Adriane
    Ribeiro, Leticia
    NEURO-ONCOLOGY, 2016, 18 : 124 - 124
  • [33] Epidemiology of pediatric central nervous system tumors in Uyghur: experience from a single center
    Wu, Xuchao
    Geng, Dangmurenjiafu
    Fan, Guofeng
    Zeng, Jia
    Zhao, Xiaoyu
    Sheng, Chengjun
    Zhu, Guohua
    CHILDS NERVOUS SYSTEM, 2023, 39 (04) : 909 - 914
  • [34] Epidemiology of pediatric central nervous system tumors in Uyghur: experience from a single center
    Xuchao Wu
    Guofeng Dangmurenjiafu·Geng
    Jia Fan
    Xiaoyu Zeng
    Chengjun Zhao
    Guohua Sheng
    Child's Nervous System, 2023, 39 : 909 - 914
  • [35] Clinical Outcomes of RTOG 9310 Protocol for Primary Central Nervous System Lymphoma: Single-Center Experience with 87 Patients
    Kim, Jinuk
    Kim, Tae Gyu
    Lee, Hyoun Wook
    Kim, Seok Hyun
    Park, Ji Eun
    Lee, Moonok
    Kim, Young Zoon
    CURRENT ONCOLOGY, 2021, 28 (06) : 4655 - 4672
  • [36] Reply: Liver Grafts from Donors with Central Nervous System Tumors: A Single-Center Perspective
    Schiff, David
    LIVER TRANSPLANTATION, 2010, 16 (07) : 916 - 916
  • [37] The Outcome of Children With Malignant Bone Tumors: A Single-Center Experience
    Bordbar, Mohammadreza
    Sarfaraz, Ali
    Haghpanah, Sezaneh
    Zekavat, Omidreza
    Zareifar, Soheila
    Zarei, Tahereh
    GLOBAL PEDIATRIC HEALTH, 2021, 8
  • [38] THE HIDDEN FACE OF BEHCET'S SYNDROME; CENTRAL NERVOUS SYSTEM INVOLVEMENT, A SINGLE-CENTER EXPERIENCE
    Yildirim, Resit
    Dinler, Mustafa
    Arslan, Ayse E.
    Bilge, Nazife S. Y.
    Kasifoglu, Timucin
    RHEUMATOLOGY, 2022, 61 : I71 - I71
  • [39] Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience
    Bryan J. Neth
    Mason J. Webb
    Jessica White
    Joon H. Uhm
    Pavel N. Pichurin
    Ugur Sener
    Journal of Neuro-Oncology, 2023, 164 : 239 - 247
  • [40] Belzutifan in adults with VHL-associated central nervous system hemangioblastoma: a single-center experience
    Neth, Bryan J.
    Webb, Mason J.
    White, Jessica
    Uhm, Joon H.
    Pichurin, Pavel N.
    Sener, Ugur
    JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (01) : 239 - 247